Literature DB >> 5121653

Phase I study of dibromodulcitol (NSC-104800).

N C Andrews, A J Weiss, F J Ansfield, D B Rochlin, J H Mason.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5121653

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  The chemotherapy of large-bowel cancer. Present status and future prospects.

Authors:  J Horton; C B Hacker; T J Cunningham; R W Sponzo
Journal:  Am J Dig Dis       Date:  1974-11

3.  The binding of in vivo administered dibromodulcitol to the DNA, histone and non-histone of Yoshida ascites tumor cells.

Authors:  E Institóris; L Holczinger; D Bánfi
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1974

4.  Comparative studies on the in vivo distribution pattern of dibromodulcitol and diepoxydulcitol.

Authors:  G Pethes
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1973

5.  Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.

Authors:  D A Amato; H Bruckner; D Guerry; A Ash; G Falkson; E C Borden; R H Creech; E D Savlov; T J Cunningham
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.